JP2015518832A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518832A5 JP2015518832A5 JP2015512770A JP2015512770A JP2015518832A5 JP 2015518832 A5 JP2015518832 A5 JP 2015518832A5 JP 2015512770 A JP2015512770 A JP 2015512770A JP 2015512770 A JP2015512770 A JP 2015512770A JP 2015518832 A5 JP2015518832 A5 JP 2015518832A5
- Authority
- JP
- Japan
- Prior art keywords
- pab
- lys
- val
- active drug
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 15
- 229940079593 drugs Drugs 0.000 claims 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 230000035982 PAB Effects 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 102000005614 monoclonal antibodies Human genes 0.000 claims 4
- 108010045030 monoclonal antibodies Proteins 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229920001542 oligosaccharide Polymers 0.000 claims 4
- 150000002482 oligosaccharides Polymers 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 3
- FADYJNXDPBKVCA-UHFFFAOYSA-N Phenylalanyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 claims 3
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 claims 3
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 108010073969 valyllysine Proteins 0.000 claims 3
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims 2
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229960000060 monoclonal antibodies Drugs 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
Claims (14)
- 式Ia:
Aは標的部分であり、
Bは第二の標的部分を含んでいてよい補助的部分であるか、またはBは存在せず、
XはN(窒素)またはCHであり、
YはN(窒素)またはCHであり、
mは0、1、または2であり、
Dはそれぞれ独立して選択され、ここで、各Dは活性薬物であり、
L 2 はそれぞれ独立して、リンカーであり、ここで、少なくとも1個のL 2 はL 1A に結合し、
nは1、2、3、4、5、6、7、8、9または10であり、
Lはリンカーであるか、または存在せず、そして
L1A はリンカーであるか、または存在しない。]
を含む、活性薬物複合体またはその薬学的に許容される塩。 -
- Lが−NH−C(=O)−、−NH−C(=O)−NH−および−NH−C(=O)−O−からなる群より選択されるかまたは存在しない、請求項1または2に記載の活性薬物複合体。
- 式Iaの構造が式Iaa
- 式Iaの構造が、式Iab
- L1Aが−(CH2)n−、−(CH 2 CH 2 O) n −、Val−Cit−PAB、Val−Ala−PAB、Val−Lys(Ac)−PAB、Phe−Lys−PAB、Phe−Lys(Ac)−PAB、D−Val−Leu−Lys、Gly−Gly−Arg、Ala−Ala−Asn−PAB、Ala−PAB、PAB、ペプチド、オリゴ糖またはそれらの組み合わせからなる群より選択される、請求項4または5に記載の活性薬物複合体。
- 構成要素Aがモノクローナル抗体(mAB)、抗体フラグメント、サロゲートもしくは変異体、タンパク質リガンド、タンパク質骨格、ペプチド、小分子リガンド、少なくとも1個の修飾されたn−ブチルL−α−アミノ酸残基、L 1A の少なくとも1個の窒素に結合する少なくとも1個の修飾されたn−ブチルL−α−アミノ酸残基、L 1A の少なくとも1個の窒素が複合体形成前の構成要素AのL−リシン残基由来であるものおよびL 1A の少なくとも1個のN(窒素)原子を提供するL−リシン残基の側鎖の−(CH 2 ) 4 −からなる群より選択される、請求項1ないし6のいずれかに記載の活性薬物複合体。
- 構成要素AとL1A が一体となって、少なくとも1個の修飾されたL−リシン残基を含む、請求項1に記載の活性薬物複合体。
- L2 がペプチド、オリゴ糖、−(CH2)−、O(酸素)、S(硫黄)、−NH−、−(CH2CH2O)−、Val、Cit、PAB、Phe、Lys、D−Val、Leu、Lys、Gly、Ala、Asn、−(CH 2 ) n 、−(CH 2 CH 2 O) n 、Val−Cit−PAB、Val−Ala−PAB、Val−Lys(Ac)−PAB、Phe−Lys−PAB、Phe−Lys(Ac)−PAB、D−Val−Leu−Lys、Gly−Gly−Arg、Ala−Ala−Asn−PAB、Ala−PAB、ペプチド、オリゴ糖およびそれらの組み合わせからなる群より選択される少なくとも1個の要素を含む、請求項1ないし8のいずれか一項に記載の活性薬物複合体。
- 構成要素Aがモノクローナル抗体(mAB)、抗体フラグメント、サロゲートまたは変異体、タンパク質リガンド、タンパク質骨格、ペプチド、小分子リガンドおよび少なくとも1個の修飾されたL−アラニン残基からなる群より選択される、請求項9に記載の活性薬物複合体。
- 少なくとも1個のL2が、−(CH2)n−、−(CH 2 CH 2 O) n −、Val−Cit−PAB、Val−Ala−PAB、Val−Lys(Ac)−PAB、Phe−Lys−PAB、Phe−Lys(Ac)−PAB、D−Val−Leu−Lys、Gly−Gly−Arg、Ala−Ala−Asn−PAB、Ala−PAB、PAB、ペプチド、オリゴ糖およびそれらの組み合わせからなる群より選択される、請求項1ないし10のいずれか一項に記載の活性薬物複合体。
- Lが、−C(=O)−、−NH−C(=O)−、−C(=O)−O−、−NH−C(=O)−NH−または−NH−C(=O)−O−を含む、請求項1ないし11のいずれか一項に記載の活性薬物複合体。
- 式I−Aのアミンを式I−Bのジアルデヒドと反応させて、
- 式II−Aの化合物を式II−Bの化合物と反応させて、
Rは、所望により置換されていてよいアルキル、所望により置換されていてよいアリール、または置換ヘテロ環である。]
活性薬物複合体を得る、化学的合成法。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261647300P | 2012-05-15 | 2012-05-15 | |
US61/647,300 | 2012-05-15 | ||
US201261648406P | 2012-05-17 | 2012-05-17 | |
US201261648532P | 2012-05-17 | 2012-05-17 | |
US61/648,532 | 2012-05-17 | ||
US61/648,406 | 2012-05-17 | ||
US201261652512P | 2012-05-29 | 2012-05-29 | |
US61/652,512 | 2012-05-29 | ||
PCT/US2013/041027 WO2013173392A1 (en) | 2012-05-15 | 2013-05-14 | Drug-conjugates, conjugation methods, and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017212167A Division JP2018052951A (ja) | 2012-05-15 | 2017-11-01 | 薬物複合体、複合体形成方法、およびその使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015518832A JP2015518832A (ja) | 2015-07-06 |
JP2015518832A5 true JP2015518832A5 (ja) | 2016-06-30 |
JP6239598B2 JP6239598B2 (ja) | 2017-11-29 |
Family
ID=49584226
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015512771A Active JP6280103B2 (ja) | 2012-05-15 | 2013-05-14 | 薬物コンジュゲート、コンジュゲーション方法およびその使用 |
JP2015512769A Active JP6239597B2 (ja) | 2012-05-15 | 2013-05-14 | 薬物コンジュゲート、コンジュゲーション方法およびその使用 |
JP2015512770A Active JP6239598B2 (ja) | 2012-05-15 | 2013-05-14 | 薬物複合体、複合体形成方法、およびその使用 |
JP2017212053A Pending JP2018058851A (ja) | 2012-05-15 | 2017-11-01 | 薬物コンジュゲート、コンジュゲーション方法およびその使用 |
JP2017212167A Pending JP2018052951A (ja) | 2012-05-15 | 2017-11-01 | 薬物複合体、複合体形成方法、およびその使用 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015512771A Active JP6280103B2 (ja) | 2012-05-15 | 2013-05-14 | 薬物コンジュゲート、コンジュゲーション方法およびその使用 |
JP2015512769A Active JP6239597B2 (ja) | 2012-05-15 | 2013-05-14 | 薬物コンジュゲート、コンジュゲーション方法およびその使用 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017212053A Pending JP2018058851A (ja) | 2012-05-15 | 2017-11-01 | 薬物コンジュゲート、コンジュゲーション方法およびその使用 |
JP2017212167A Pending JP2018052951A (ja) | 2012-05-15 | 2017-11-01 | 薬物複合体、複合体形成方法、およびその使用 |
Country Status (7)
Country | Link |
---|---|
US (6) | US9981046B2 (ja) |
EP (6) | EP2850059A4 (ja) |
JP (5) | JP6280103B2 (ja) |
CN (4) | CN104662000B (ja) |
ES (2) | ES2887208T3 (ja) |
HK (3) | HK1208163A1 (ja) |
WO (3) | WO2013173391A1 (ja) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1789391B1 (en) | 2004-07-23 | 2017-06-28 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
EP2139523B1 (en) | 2007-03-14 | 2014-10-22 | Endocyte, Inc. | Conjugates of folate and tubulysin for targeted drug delivery |
BRPI0812970A2 (pt) | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
CN104662000B (zh) | 2012-05-15 | 2018-08-17 | 索伦托医疗有限公司 | 药物偶联物及其偶联方法和用途 |
MX2015004757A (es) | 2012-10-16 | 2015-07-17 | Endocyte Inc | Conjugados de suministro de farmacos que contienen aminoacidos no naturales y metodo para usarlos. |
SG11201504887TA (en) | 2012-12-21 | 2015-07-30 | Bioalliance Cv | Hydrophilic self-immolative linkers and conjugates thereof |
SG11201507619PA (en) | 2013-03-15 | 2015-10-29 | Ct For Drug Res And Dev | Cytotoxic and anti-mitotic compounds, and methods of using the same |
CA2914448A1 (en) | 2013-06-12 | 2014-12-18 | Muhammad Naveed Yousaf | Compounds for promoting liposomal and cellular adhesion and compositions and methods of use thereof |
EP3035938B1 (en) | 2013-09-10 | 2020-08-19 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
SG11201604879QA (en) | 2013-10-15 | 2016-07-28 | Sorrento Therapeutics Inc | Drug-conjugates with a targeting molecule and two different drugs |
PT3057585T (pt) | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
WO2015066053A2 (en) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
WO2015095952A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Var2csa-drug conjugates |
WO2015095953A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Sulfonamide-containing linkage systems for drug conjugates |
JP6664329B2 (ja) * | 2014-01-28 | 2020-03-13 | トゥーベ・ファルマシューティカルズ・ゲー・エム・ベー・ハー | コンジュゲーションのための新規な細胞毒性チューブリシン化合物 |
JP2017505777A (ja) | 2014-01-29 | 2017-02-23 | シンタ ファーマスーティカルズ コーポレーション | 標的化治療薬 |
GB201402006D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
CN106456795A (zh) | 2014-03-03 | 2017-02-22 | 辛塔医药品有限公司 | 靶向治疗学 |
MA39483A (fr) | 2014-03-18 | 2015-09-24 | Synta Pharmaceuticals Corp | Agents thérapeutiques cibles |
SG11201609739UA (en) * | 2014-05-28 | 2016-12-29 | Agensys Inc | Derivatives of dolaproine-dolaisoleuine peptides |
JP2017528418A (ja) | 2014-06-20 | 2017-09-28 | バイオアライアンス コマンディテール フェンノートシャップ | 抗葉酸受容体アルファ(fra)抗体−薬物コンジュゲート及びその使用方法 |
SI3169706T1 (sl) | 2014-07-11 | 2020-04-30 | Genmab A/S | Protitelesa, ki vežejo AXL |
EP3191502B1 (en) * | 2014-09-11 | 2021-04-21 | Seagen Inc. | Targeted delivery of tertiary amine-containing drug substances |
CN107001415B (zh) * | 2014-09-17 | 2021-06-18 | 酵活有限公司 | 细胞毒性和抗有丝分裂化合物、及其使用方法 |
EP3218009B1 (en) | 2014-10-14 | 2021-04-07 | Polytherics Limited | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
CA2969892A1 (en) * | 2014-12-08 | 2016-06-16 | Sorrento Therapeutics, Inc. | C-met antibody drug conjugate |
US9968683B2 (en) | 2014-12-17 | 2018-05-15 | Organolinx Corp. | Method for conjugating molecules |
EP3250238B1 (en) * | 2015-01-28 | 2022-06-01 | Sorrento Therapeutics, Inc. | Antibody drug conjugates |
CN107635405A (zh) * | 2015-02-06 | 2018-01-26 | 索伦托医疗有限公司 | 抗体药物缀合物 |
KR20170117473A (ko) * | 2015-02-15 | 2017-10-23 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 리간드-세포독성 약물 접합체, 이의 제조 방법 및 이의 적용 |
CN106279352B (zh) | 2015-05-29 | 2020-05-22 | 上海新理念生物医药科技有限公司 | 海兔毒素10的衍生物及其应用 |
EP3308801A4 (en) | 2015-06-09 | 2019-02-27 | XDCExplorer (Shanghai) Co., Ltd. | ANTIBODY-MEDICINAL CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
LT3319993T (lt) | 2015-07-10 | 2020-05-11 | Genmab A/S | Axl specifiniai antikūno-vaistokonjugatai, skirti vėžiui gydyti |
CA2991973C (en) | 2015-07-12 | 2021-12-07 | Suzhou M-Conj Biotech Co., Ltd. | Bridge linkers for conjugation of a cell-binding molecule |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
WO2017054080A1 (en) * | 2015-09-29 | 2017-04-06 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
WO2017058808A1 (en) * | 2015-10-02 | 2017-04-06 | Sirenas Llc | Anti-cancer compounds and conjugates thereof |
TWI660741B (zh) | 2015-11-03 | 2019-06-01 | 財團法人工業技術研究院 | 抗體藥物複合物及其製造方法 |
CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
MX2018006218A (es) | 2015-12-04 | 2018-09-05 | Seattle Genetics Inc | Conjugados de compuestos de tubulisina cuaternizada. |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
CN108713026B (zh) | 2016-01-08 | 2023-01-06 | 美国全心医药生技股份有限公司 | 四价抗psgl-1抗体及其用途 |
CN107029244B (zh) * | 2016-02-04 | 2021-04-27 | 浙江昭华生物医药有限公司 | 抗her2抗体-药物偶联物及其应用 |
SG10202007520WA (en) | 2016-03-02 | 2020-09-29 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
BR112018069273A2 (pt) | 2016-03-25 | 2019-01-22 | Seattle Genetics Inc | métodos para preparação de um composto e para tratamento de um indivíduo com uma malignidade hematológica, composto, composição, e, intermediário ligante de fármaco ou composto ligante de fármaco |
CN108779146B (zh) * | 2016-03-29 | 2022-03-18 | 东丽株式会社 | 肽衍生物及其用途 |
US20170281758A1 (en) * | 2016-03-29 | 2017-10-05 | Sorrento Therapeutics, Inc. | Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin |
MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
EP3471771A4 (en) * | 2016-05-31 | 2020-04-15 | Sorrento Therapeutics, Inc. | ANTIBODY CONJUGATES HAVING AMATOXIN DERIVATIVES AS A MEDICINAL PRODUCT |
MX2018015684A (es) | 2016-06-17 | 2019-08-29 | Magenta Therapeutics Inc | Composiciones y metodos para el agotamiento de celulas cd117. |
CN108697809A (zh) * | 2016-08-23 | 2018-10-23 | 四川科伦博泰生物医药股份有限公司 | 一种抗体-药物偶联物及其制备方法和应用 |
US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
ES2921236T3 (es) * | 2016-11-25 | 2022-08-22 | Mabwell Shanghai Bioscience Co Ltd | Enlazador de amida maleica disustituida para la conjugación de anticuerpo y fármaco y método de preparación y uso del mismo |
CN108101825B (zh) * | 2016-11-25 | 2022-02-22 | 迈威(上海)生物科技股份有限公司 | 用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途 |
CN109810039B (zh) * | 2017-11-22 | 2021-11-12 | 迈威(上海)生物科技股份有限公司 | 一种用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途 |
US10864279B2 (en) | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
WO2018134787A2 (en) | 2017-01-20 | 2018-07-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd137+ cells |
MX2019010769A (es) | 2017-03-24 | 2019-12-11 | Seattle Genetics Inc | Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos. |
SG11201908721TA (en) * | 2017-04-06 | 2019-10-30 | Hangzhou Dac Biotech Co Ltd | Conjugation of a cytotoxic drug with bis-linkage |
EP3617221A4 (en) | 2017-04-19 | 2021-04-14 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | CYTOTOXIN AND CONJUGATE, USES THEREOF AND MANUFACTURING PROCESSES THEREFORE |
WO2018235024A1 (en) * | 2017-06-20 | 2018-12-27 | Sorrento Therapeutics, Inc. | CONJUGATED MEDICINE ANTI-CD38 ANTIBODY |
EP3641647A4 (en) | 2017-06-20 | 2021-05-05 | Madrigal Pharmaceuticals, Inc. | TARGETED THERAPEUTICS |
CA3067463A1 (en) | 2017-06-20 | 2018-12-27 | Madrigal Pharmaceuticals, Inc. | Combination therapies comprising targeted therapeutics |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
US10799598B2 (en) | 2017-08-01 | 2020-10-13 | Sorrento Therapeutics, Inc. | Disulfide bridging conjugates |
CN111051329A (zh) | 2017-08-10 | 2020-04-21 | 大日本住友制药株式会社 | 哈米特林衍生物及它们的抗体药物复合物 |
JP2020533308A (ja) | 2017-09-08 | 2020-11-19 | シアトル ジェネティックス, インコーポレイテッド | チューブリシンおよびそれらの中間体の調製のためのプロセス |
CN111655268B (zh) | 2017-10-04 | 2024-03-26 | 艾维迪提生物科学公司 | 核酸-多肽组合物及其用途 |
WO2019108797A1 (en) | 2017-11-30 | 2019-06-06 | Seattle Genetics, Inc. | Process for the preparation of drug linker compounds |
MA51103A (fr) | 2017-12-06 | 2020-10-14 | Avidity Biosciences Inc | Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique |
CN113603703A (zh) | 2017-12-15 | 2021-11-05 | 四川科伦博泰生物医药股份有限公司 | 生物活性物偶联物及其制备方法和用途 |
CN110090308B (zh) * | 2018-01-30 | 2023-03-24 | 四川科伦博泰生物医药股份有限公司 | 制备偶联物的方法 |
JP2021513990A (ja) * | 2018-02-20 | 2021-06-03 | シージェン インコーポレイテッド | 疎水性アウリスタチンf化合物およびそのコンジュゲート |
EP3801523A2 (en) | 2018-06-01 | 2021-04-14 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
TW202015739A (zh) | 2018-06-01 | 2020-05-01 | 日商衛材R&D企管股份有限公司 | 剪接調節抗體-藥物結合物及其使用方法 |
US20210276971A1 (en) | 2018-06-20 | 2021-09-09 | The Research Foundation For The State University Of New York | Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
KR20210102274A (ko) | 2018-12-13 | 2021-08-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 헤르복시디엔 항체-약물 접합체 및 사용 방법 |
AU2019406199A1 (en) | 2018-12-21 | 2021-07-29 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibodies and uses thereof |
SG11202106122QA (en) * | 2018-12-21 | 2021-07-29 | Seagen Inc | Adcs with thiol multiplex linkers |
EP3918323A4 (en) | 2019-01-30 | 2022-12-28 | TrueBinding, Inc. | ANTI-GAL3 ANTIBODIES AND THEIR USES |
CN109824759A (zh) * | 2019-03-08 | 2019-05-31 | 联宁(苏州)生物制药有限公司 | 一种用于抗体药物偶联物的药物-连接子mc-mmaf的制备方法及其中间体 |
JP2022535588A (ja) | 2019-06-06 | 2022-08-09 | アビディティー バイオサイエンシーズ,インク. | 核酸ポリペプチド組成物およびその使用 |
WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
EP4090379A1 (en) | 2020-01-13 | 2022-11-23 | Synaffix B.V. | Via cycloaddition bilaterally functionalized antibodies |
JP2023511857A (ja) | 2020-01-13 | 2023-03-23 | シンアフィックス ビー.ブイ. | 付加環化を介して両側官能化された抗体 |
EP4090377A1 (en) | 2020-01-13 | 2022-11-23 | Synaffix B.V. | Conjugates of antibodies an immune cell engagers |
JP2023515573A (ja) | 2020-02-26 | 2023-04-13 | ソレント・セラピューティクス・インコーポレイテッド | 普遍的な遮蔽性部分を有する活性化可能な抗原結合性タンパク質 |
JP2023519169A (ja) * | 2020-03-09 | 2023-05-10 | シグマ-アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー | 一般的な中間体を介したドラスタチンおよびオーリスタチン類似体の効率的な調製 |
CN115666589A (zh) | 2020-03-19 | 2023-01-31 | 艾维迪提生物科学公司 | 治疗面肩肱型肌营养不良的组合物和方法 |
TW202202173A (zh) | 2020-03-27 | 2022-01-16 | 美商亞維代堤生物科學公司 | 治療肌肉萎縮症之組合物及方法 |
KR20230020441A (ko) | 2020-06-05 | 2023-02-10 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항-bcma 항체-약물 컨쥬게이트 및 이용 방법 |
WO2021260232A1 (en) | 2020-06-26 | 2021-12-30 | Synaffix B.V. | Methods for the preparation of linker payload constructs |
NL2026400B1 (en) | 2020-09-02 | 2022-05-04 | Synaffix Bv | Methods for the preparation of bioconjugates |
EP4208259A2 (en) | 2020-09-04 | 2023-07-12 | NovaRock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
WO2022058395A1 (en) | 2020-09-15 | 2022-03-24 | Synaffix B.V. | Antibody-exatecan conjugates |
NL2026947B1 (en) | 2020-11-20 | 2022-07-01 | Synaffix Bv | Tyrosine-based antibody conjugates |
KR20230124684A (ko) | 2020-12-23 | 2023-08-25 | 루드비히-막시밀리안스-우니버지테트 뮌헨 | 개선된 cd30 표적화 항체 약물 접합체 및 이의 용도 |
JP2024506022A (ja) | 2021-02-08 | 2024-02-08 | シンアフィックス ビー.ブイ. | 多機能性抗体 |
CA3210069A1 (en) | 2021-03-03 | 2022-09-09 | Tong Zhu | Antibody-drug conjugates comprising an anti-bcma antibody |
EP4308242A1 (en) | 2021-03-17 | 2024-01-24 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
CN116897149A (zh) * | 2021-03-30 | 2023-10-17 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
EP4370555A1 (en) | 2021-07-13 | 2024-05-22 | TrueBinding, Inc. | Methods of preventing protein aggregation |
IL311452A (en) | 2021-09-16 | 2024-05-01 | Avidity Biosciences Inc | Compositions and methods for the treatment of FSHD muscular dystrophy |
WO2023122347A2 (en) | 2021-12-23 | 2023-06-29 | Mirecule, Inc. | Compositions for delivery of polynucleotides |
WO2023173026A1 (en) | 2022-03-10 | 2023-09-14 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024038065A1 (en) | 2022-08-15 | 2024-02-22 | Synaffix B.V. | Anthracyclins and conjugates thereof |
WO2024107765A2 (en) | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
CN116621927B (zh) * | 2023-01-09 | 2024-03-26 | 联宁(苏州)生物制药有限公司 | 带有伊喜替康和C-lock定点偶联基团的抗体偶联中间体、偶联方法及抗体偶联药物 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
US6569834B1 (en) | 1992-12-03 | 2003-05-27 | George R. Pettit | Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
ATE282630T1 (de) | 1993-10-01 | 2004-12-15 | Teikoku Hormone Mfg Co Ltd | Dolastatin-derivate |
US5525474A (en) * | 1994-01-31 | 1996-06-11 | Boehringer Mannheim Corporation | Piperidine analogs and conjugates of procainamide and NAPA |
WO2002055530A2 (en) | 2000-10-25 | 2002-07-18 | Mayo Foundation | Transcobalamin binding conjugates useful for treating abnormal cellular proliferation |
JP4477881B2 (ja) * | 2002-03-01 | 2010-06-09 | ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド | 治療剤または細胞毒性剤と生物活性ペプチドとの抱合体 |
US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
WO2004005327A1 (de) | 2002-07-09 | 2004-01-15 | Morphochem Ag Komb Chemie | Neue tubulysinanaloga |
DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
DE10254439A1 (de) | 2002-11-21 | 2004-06-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Tubulysine, Herstellungsverfahren und Tubulysin-Mittel |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
NO347360B1 (no) * | 2003-10-10 | 2023-09-25 | Immunogen Inc | Cellebindingsmiddelmaytansinoid-konjugat med formel trastuzumab-SMCC-DM1 eller trastuzumab-SIABDM1, fremgangsmåte for fremstilling av disse og en in vitro fremgangsmåte for å styre maytansinoider til en valgt cellepopulasjon eller for å eliminere celler, samt anvendelse. |
DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
US20070134243A1 (en) * | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
WO2006060533A2 (en) | 2004-12-01 | 2006-06-08 | Genentech, Inc. | Conjugates of 1, 8-bis-naphthalimides with an antibody |
JP2008537673A (ja) | 2005-01-31 | 2008-09-25 | ジェネンテック・インコーポレーテッド | 抗ephb2抗体とその使用方法 |
EA016577B1 (ru) * | 2005-09-26 | 2012-06-29 | Медарекс, Инк. | Конъюгаты антитело-лекарство и их применение |
AR059900A1 (es) * | 2006-03-17 | 2008-05-07 | Genentech Inc | Anticuerpos anti-tat226 e inmunoconjugados |
CL2007001630A1 (es) | 2006-06-06 | 2008-02-08 | Enanta Pharm Inc | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. |
US9415111B2 (en) * | 2006-08-11 | 2016-08-16 | Rutgers, The State University Of New Jersey | Dual-sensitizer-containing luminescent compounds, conjugates, and uses thereof |
WO2008022309A2 (en) * | 2006-08-18 | 2008-02-21 | F. Hoffmann-La Roche Ag | Polyconjugates for in vivo delivery of polynucleotides |
EP2139523B1 (en) | 2007-03-14 | 2014-10-22 | Endocyte, Inc. | Conjugates of folate and tubulysin for targeted drug delivery |
US8569834B2 (en) | 2007-04-12 | 2013-10-29 | The Penn State Research Foundation | Accumulation field effect microelectronic device and process for the formation thereof |
BRPI0812970A2 (pt) * | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
EP2181101A2 (en) * | 2007-07-20 | 2010-05-05 | Helmholtz-Zentrum für Infektionsforschung GmbH | Tubulysin d analogues |
US8900589B2 (en) | 2008-07-15 | 2014-12-02 | Genetech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
JP5675619B2 (ja) * | 2008-09-17 | 2015-02-25 | エンドサイト, インク.Endocyte, Inc. | 葉酸拮抗薬の葉酸受容体結合性コンジュゲート |
EP2174947A1 (en) * | 2008-09-25 | 2010-04-14 | Universität des Saarlandes | Bioactive pre-tubulysins and use thereof |
US9211319B2 (en) * | 2009-01-09 | 2015-12-15 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates |
EP2403538B1 (en) | 2009-03-04 | 2017-10-04 | Polytherics Limited | Conjugated proteins and peptides |
US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
MX2012008884A (es) | 2010-02-08 | 2012-08-31 | Agensys Inc | Conjugados de anticuerpo y farmaco (adc) que se unen a proteinas 161p2f10b. |
NZ602840A (en) * | 2010-06-03 | 2014-11-28 | Genentech Inc | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
WO2011156328A1 (en) * | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP2409983A1 (en) * | 2010-07-19 | 2012-01-25 | Leibniz-Institut für Pflanzenbiochemie (IPB) | Tubulysin analogues |
CN103379912B (zh) | 2010-09-29 | 2016-03-16 | 西雅图基因公司 | 正羧烷基耳他汀及其应用 |
KR101897307B1 (ko) | 2010-12-02 | 2018-09-10 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 모르폴리닐 안트라사이클린 유도체의 제조 방법 |
MX359217B (es) | 2011-05-27 | 2018-09-19 | Ambrx Inc | Composiciones que contienen, métodos que involucran, y usos de derivados de dolastatina unidos a aminoácidos no naturales. |
EP2714685B1 (en) | 2011-05-27 | 2016-10-19 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2012177837A2 (en) | 2011-06-21 | 2012-12-27 | Immunogen, Inc. | Novel maytansinoid derivatives with peptide linker and conjugates thereof |
IN2014CN04961A (ja) | 2011-12-05 | 2015-09-18 | Igenica Biotherapeutics Inc | |
CN104662000B (zh) | 2012-05-15 | 2018-08-17 | 索伦托医疗有限公司 | 药物偶联物及其偶联方法和用途 |
SG11201408153YA (en) | 2012-06-07 | 2015-01-29 | Ambrx Inc | Prostate-specific membrane antigen antibody drug conjugates |
ES2712648T3 (es) | 2012-06-19 | 2019-05-14 | Ambrx Inc | Conjugados de fármaco de anticuerpo anti-CD70 |
JP6297550B2 (ja) | 2012-07-09 | 2018-03-20 | ジェネンテック, インコーポレイテッド | 抗cd79b抗体を含む免疫複合体 |
SG11201604879QA (en) | 2013-10-15 | 2016-07-28 | Sorrento Therapeutics Inc | Drug-conjugates with a targeting molecule and two different drugs |
EP3250238B1 (en) | 2015-01-28 | 2022-06-01 | Sorrento Therapeutics, Inc. | Antibody drug conjugates |
CN107635405A (zh) | 2015-02-06 | 2018-01-26 | 索伦托医疗有限公司 | 抗体药物缀合物 |
-
2013
- 2013-05-14 CN CN201380025775.8A patent/CN104662000B/zh active Active
- 2013-05-14 ES ES19167808T patent/ES2887208T3/es active Active
- 2013-05-14 CN CN201710584374.6A patent/CN107982545B/zh active Active
- 2013-05-14 EP EP13790777.0A patent/EP2850059A4/en not_active Ceased
- 2013-05-14 US US14/401,115 patent/US9981046B2/en active Active
- 2013-05-14 JP JP2015512771A patent/JP6280103B2/ja active Active
- 2013-05-14 EP EP19167808.5A patent/EP3590541B1/en active Active
- 2013-05-14 CN CN201380025774.3A patent/CN104379168B/zh active Active
- 2013-05-14 EP EP21189993.5A patent/EP3925627A1/en active Pending
- 2013-05-14 WO PCT/US2013/041026 patent/WO2013173391A1/en active Application Filing
- 2013-05-14 JP JP2015512769A patent/JP6239597B2/ja active Active
- 2013-05-14 EP EP13790623.6A patent/EP2849790B1/en active Active
- 2013-05-14 US US14/401,114 patent/US9884127B2/en active Active
- 2013-05-14 EP EP18199921.0A patent/EP3520817A1/en active Pending
- 2013-05-14 WO PCT/US2013/041028 patent/WO2013173393A1/en active Application Filing
- 2013-05-14 US US14/401,318 patent/US9801951B2/en active Active
- 2013-05-14 ES ES13790623T patent/ES2734259T3/es active Active
- 2013-05-14 CN CN201380025785.1A patent/CN104640572B/zh active Active
- 2013-05-14 EP EP13790334.0A patent/EP2849797B1/en active Active
- 2013-05-14 JP JP2015512770A patent/JP6239598B2/ja active Active
- 2013-05-14 WO PCT/US2013/041027 patent/WO2013173392A1/en active Application Filing
-
2015
- 2015-09-09 HK HK15108781.9A patent/HK1208163A1/xx unknown
- 2015-09-09 HK HK15108785.5A patent/HK1208165A1/xx unknown
- 2015-09-09 HK HK15108783.7A patent/HK1208216A1/xx unknown
-
2017
- 2017-08-17 US US15/679,599 patent/US20180085471A1/en not_active Abandoned
- 2017-11-01 JP JP2017212053A patent/JP2018058851A/ja active Pending
- 2017-11-01 JP JP2017212167A patent/JP2018052951A/ja active Pending
- 2017-12-26 US US15/854,742 patent/US10967071B2/en active Active
-
2021
- 2021-03-01 US US17/189,135 patent/US20210187119A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015518832A5 (ja) | ||
JP2020513855A5 (ja) | ||
JP2015518831A5 (ja) | ||
JP2011500725A5 (ja) | ||
JP2016153410A5 (ja) | ||
JP2010529957A5 (ja) | ||
JP7429726B2 (ja) | α4β7インテグリンを標的とする環状ペプチド多量体 | |
RU2016130933A (ru) | Сульфонамид-содержащие связывающие системы для лекарственных конъюгатов | |
JP2010511388A5 (ja) | ||
JP2017525755A5 (ja) | ||
PE20040942A1 (es) | Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes | |
JP2019506841A5 (ja) | ||
RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
JP2006507265A5 (ja) | ||
RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
JP2004529963A5 (ja) | ||
JP2008504237A5 (ja) | ||
FI3796912T3 (fi) | Antiproliferatiivisia yhdisteitä ja bcma:n ja cd3:n vastainen bispesifinen vasta-aine yhdistelmäkäyttöön | |
JP2014516924A5 (ja) | ||
JP2011522795A5 (ja) | ||
JP2009529915A5 (ja) | ||
JP2006521361A5 (ja) | ||
HRP20220123T1 (hr) | Citotoksični i antimitotički spojevi, te postupci njihove uporabe | |
JPWO2020259258A5 (ja) | ||
JP7274425B2 (ja) | α4β7インテグリンを標的とするホモデチック環状ペプチド |